Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
The French drugmaker reported adjusted EPS of $0.93 (1.73 euros), beating the consensus estimate of $0.86, down 0.6% reported and up 4.0% at CER.On Thursday, Sanofi SA (NASDAQ:SNY) reported a second-quarter business operating income of 2.8 billion euros ($3.03 billion), up 3.2% year-over-year and 8.3% in constant currency.
賽諾菲安萬特(NASDAQ: SNY)週四發佈第二季度業務運營收入28億歐元($30.3億)，同比增長3.2%，全球貨幣增長近8.3%。
The company reported second-quarter sales of $11.57 billion (10.75 billion euros), beating the consensus of $11.37 billion. Sales increased 7.8% year over year and 10.2% on constant currency.
該公司第二季度銷售額爲115.7億美元(107.5億歐元)，超過了市場預期的113.7億美元。銷售額同比增長7.8%，全球貨幣增長10.2%。
Also Read: Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data.
歐洲批准賽諾菲/再生元的杜比塞特用於“菸民肺”，美國FDA要求提供數據後一個月。
The French drugmaker reported adjusted EPS of $0.93 (1.73 euros), beating the consensus estimate of $0.86, down 0.6% reported and up 4.0% at CER.
這家法國藥企報告調整後每股收益0.93美元(1.73歐元)，超過了預期的0.86美元，按報告計算下降了0.6%，全球貨幣增長了4.0%。
Sales of Dupixent, Sanofi's blockbuster eczema drug, rose 29.2% to 3.30 billion euros. Reuters notes that the drug on which Sanofi partners with Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has long been a growth driver.
賽諾菲的大規模溼疹藥物Dupixent的銷售額增長了29.2%，達到33億歐元。路透社指出，賽諾菲與再生元製藥公司(NASDAQ: REGN)合作開發的這種藥物一直是增長驅動因素。
Despite expanding its use for other conditions, Sanofi faces shareholder concerns about its heavy reliance on the drug.
儘管擴大了用於其他疾病的使用，賽諾菲面臨股東對其對這種藥物的過度依賴的擔憂。
Sales of another new medicine, Altuviiio for hemophilia, were 158 million euros.
新藥阿奇佛治療血友病的銷售額爲1.58億歐元。
Sales of Beyfortus, a treatment for RSV infection, generated 18 million euros, reflecting the global vaccine seasonality towards the second half-year.
治療RSV感染的備福特斯的銷售額爲1800萬歐元，反映出全球疫苗銷售在下半年的季節性影響。
Sanofi sells the drug in collaboration with AstraZeneca Plc (NASDAQ:AZN).
賽諾菲與阿斯利康股份有限公司(NASDAQ: AZN)合作銷售此藥。
Vaccine sales decreased by 4.8% to 1.14 million euros, which was impacted by the absence of COVID-19 sales.
疫苗銷售額減少了4.8%，降至114萬歐元，這受到COVID-19銷售的缺失影響。
Guidance: For 2024, Sanofi expects business EPS to be stable at constant currency, compared to earlier expectations of a low single-digit business EPS decline.
預期：到2024年，賽諾菲預計業務每股收益以全球貨幣計算將保持穩定，而之前的預期是業務每股收益下降個位數。
The company reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. Vaccine sales are expected to grow mid-single-digit in 2024.
該公司重申，Dupixent預計將在2024年實現約130億歐元的銷售額。疫苗銷售預計將在2024年增長中位數個位數。
Sanofi shares an ambition to reach blockbuster status (sales over $1 billion) for its Beyfortus vaccine. Sanofi expects the 2024 gross margin to decline slightly.
賽諾菲希望其備福特斯疫苗能達到超過10億美元的銷售額。賽諾菲預計2024年毛利率將略有下降。
Price Action: SNY stock is up 3.73% at $53.11 during the premarket session at the last check on Thursday.
週四盤前，SNY股票在最後一次檢查時上漲3.73%，報53.11美元。
- Sanofi's $20B Consumer Health Unit Sale: Goldman Sachs, Morgan Stanley Line Up $6.5B Financing.
- 高盛和大摩資源lof分別提供了65億美元的融資，以應對賽諾菲200億美元的消費健康部門出售。
Image by HJBC via Shutterstock
圖像來自Shutterstock用戶HJBC。